Patents by Inventor Christophe Salagnad

Christophe Salagnad has filed for patents to protect the following inventions. This listing includes patent applications that are pending as well as patents that have already been granted by the United States Patent and Trademark Office (USPTO).

  • Patent number: 8765910
    Abstract: The invention relates to a method for producing C-terminal amidated dibasic or polybasic peptides, consisting in reacting two peptides in the presence of trypsin biologically active enzymes and, if necessary, in purifying the thus obtainable compounds of formula (I) by means of protein chemistry.
    Type: Grant
    Filed: September 13, 2006
    Date of Patent: July 1, 2014
    Assignee: Sanofi-Aventis Deutschland GmbH
    Inventors: Sebastian Rissom, Paul Habermann, Christophe Salagnad, Frank Zocher, Laure Landric-Burtin
  • Patent number: 7939293
    Abstract: The invention relates to the production of carboxy-terminal (C-terminal) amidified peptides with C-terminal amidified lysin, in particular with the biological activity of GLP-1, the chemical and/or biotechnological precursors and intermediate products thereof. The invention also relates to a method for the production and use thereof for producing pharmaceutical products.
    Type: Grant
    Filed: November 18, 2005
    Date of Patent: May 10, 2011
    Assignee: Sanofi-Aventis Deutschland GmbH
    Inventors: Paul Habermann, Heinrich Decker, Claus Lattemann, Oliver Maneg, Christophe Salagnad, Frank Zocher
  • Publication number: 20100311112
    Abstract: The invention relates to a method for producing C-terminal amidated dibasic or polybasic peptides, consisting in reacting two peptides in the presence of trypsin biologically active enzymes and, if necessary, in purifying the thus obtainable compounds of formula (I) by means of protein chemistry.
    Type: Application
    Filed: September 13, 2006
    Publication date: December 9, 2010
    Applicant: SANOFI-AVENTIS DEUTSCHLAND GMBH
    Inventors: Sebastian Rissom, Paul Habermann, Christophe Salagnad, Frank Zocher, Laure Landric-Burtin
  • Patent number: 7803950
    Abstract: The invention relates generally to a process for preparing diarylcycloalkyl derivatives of the formula (I). wherein the respective R-group substituents are defined herein. These compounds of formula (I) are activators for peroxisome proliferator-activated receptors (PPAR activators) which are useful in the therapeutic treatment of a number of diseases and disorders of the central nervous system such as multiple sclerosis, Parkinson's Disease, psychiatric disorders and the like. The present invention is a novel process for preparing PPAR activators of the formula (I) which do not have the disadvantages of the processes known in the prior art. In particular, a process is provided with which the PPAR activators of formula (I) can be prepared in a suitable enantiomeric excess, i.e. high enantioselectivity, without the need for subsequent chiral chromatography.
    Type: Grant
    Filed: February 20, 2007
    Date of Patent: September 28, 2010
    Assignee: Sanofi-Aventis Deutschland GmbH
    Inventors: Christophe Salagnad, Frank Zocher, Andreas Burgard, Bernd Junker, Rolf Hoerlein, Thomas Stuedemann, Claus-Jügen Maier, Jochen Hachtel, Wolfgang Holla, Christoph Tappertzhofen, Berndt Kulitzscher, Stephane Mutti
  • Publication number: 20090005299
    Abstract: The invention relates to the production of carboxy-terminal (C-terminal) amidified peptides with C-terminal amidified lysin, in particular with the biological activity of GLP-1, the chemical and/or biotechnological precursors and intermediate products thereof. The invention also relates to a method for the production and use thereof for producing pharmaceutical products.
    Type: Application
    Filed: November 18, 2005
    Publication date: January 1, 2009
    Applicant: SANOFI-AVENTIS DEUTSCHLAND GMBH
    Inventors: Paul Habermann, Heinrich Decker, Claus Lattemann, Oliver Maneg, Christophe Salagnad, Frank Zocher
  • Publication number: 20080051583
    Abstract: The invention relates generally to intermediate compounds derived during the process for preparing diarylcycloalkyl derivatives which are activators for peroxisome proliferator-activated receptors (PPAR activators) and are therefore useful in the therapeutic treatment of a number of diseases and disorders of the central nervous system such as multiple sclerosis, Parkinson's Disease, psychiatric disorders and the like. The intermediate compounds of the present invention are defined structurally by the formulae (Ia): and formula (II): wherein the respective substituent groups are defined herein.
    Type: Application
    Filed: October 31, 2007
    Publication date: February 28, 2008
    Applicant: SANOFI-AVENTIS DEUTSCHLAND GMBH
    Inventors: Christophe Salagnad, Frank Zocher, Andreas Burgard, Bernd Junker, Rolf Hoerlein, Thomas Stuedemann, Claus-Jugen Maier, Jochen Hachtel, Wolfgang Holla, Christoph Tappertzhofen, Berndt Kulitzscher, Stephane Mutti
  • Publication number: 20070197614
    Abstract: The invention relates generally to a process for preparing diarylcycloalkyl derivatives of the formula (I). wherein the respective R-group substituents are defined herein. These compounds of formula (I) are activators for peroxisome proliferator-activated receptors (PPAR activators) which are useful in the therapeutic treatment of a number of diseases and disorders of the central nervous system such as multiple sclerosis, Parkinson's Disease, psychiatric disorders and the like. The present invention is a novel process for preparing PPAR activators of the formula (I) which do not have the disadvantages of the processes known in the prior art. In particular, a process is provided with which the PPAR activators of formula (I) can be prepared in a suitable enantiomeric excess, i.e. high enantioselectivity, without the need for subsequent chiral chromatography.
    Type: Application
    Filed: February 20, 2007
    Publication date: August 23, 2007
    Applicant: SANOFI-AVENTIS DEUTSCHLAND GMBH
    Inventors: Christophe Salagnad, Frank Zocher, Andreas Burgard, Bernd Junker, Rolf Hoerlein, Thomas Stuedemann, Claus-Jugen Maier, Jochen Hachtel, Wolfgang Holla, Christoph Tappertzhofen, Berndt Kulitzscher, Stephane Mutti
  • Patent number: 6902927
    Abstract: An enzymatic process permitting the enantiomeric resolution of amino acids is provided. More specifically, this process for separating the enantiomers of an amino acid comprises treating a racemic mixture of the amino acid with glutaric anhydride and then with the enzyme glutaryl-7-ACA acylase so as to recover one of the enantiomers of the amino acid, the other enantiomer remaining in the form of the corresponding glutarylamide derivative.
    Type: Grant
    Filed: September 3, 2002
    Date of Patent: June 7, 2005
    Assignee: Aventis Pharma S.A.
    Inventors: Christophe Salagnad, Claude Gobert, Marie-Odile Dury
  • Publication number: 20030087399
    Abstract: An enzymatic process permitting the enantiomeric resolution of amino acids is provided. More specifically, this process for separating the enantiomers of an amino acid comprises treating a racemic mixture of the amino acid with glutaric anhydride and then with the enzyme glutaryl-7-ACA acylase so as to recover one of the enantiomers of the amino acid, the other enantiomer remaining in the form of the corresponding glutarylamide derivative.
    Type: Application
    Filed: September 3, 2002
    Publication date: May 8, 2003
    Inventors: Christophe Salagnad, Claude Gobert, Marie-Odile Dury
  • Patent number: 6291679
    Abstract: The present invention relates to a novel process for the preparation of benzoperhydroisindole compounds.
    Type: Grant
    Filed: July 26, 1999
    Date of Patent: September 18, 2001
    Assignee: Rhone-Poulenc Rorer S.A.
    Inventors: Patrick Mailliet, Christophe Salagnad